Evidence review · Published July 22, 2026 · Sources checked July 22, 2026

Melanotan II research overview

Melanotan II is a cyclic analogue of alpha-MSH studied as a nonselective melanocortin-receptor agonist.

Evidence boundary: published research does not establish the identity or performance of a separately supplied batch. The catalog product is supplied only for qualified in vitro laboratory research and is not for human or animal use.

What is Melanotan II acetate?

Early controlled human studies measured pigmentation and other melanocortin-associated responses, while reporting adverse effects such as nausea in selected protocols.

Research category

Endocrine & receptor signaling

Study models represented

Receptor pharmacology and small controlled human studies

Names in the literature

MT-II; Cyclic alpha-MSH analogue

Primary boundary

Small samples, nonselective receptor activity, and formulation differences limit generalization.

What does the selected evidence support?

Small early studies do not provide a general safety profile, establish unsupervised use, or verify a separately supplied acetate material.

Primary sources

1. Dorr et al., Life Sciences (1996) — Small human study evaluating pigmentation responses and tolerability. DOI: 10.1016/0024-3205(96)00160-9
2. Wessells et al., International Journal of Impotence Research (2000) — Double-blind crossover research on melanocortin-associated responses and adverse effects. DOI: 10.1038/sj.ijir.3900582

Research literature and product documentation are different

A publication describes a study and its results. A batch-specific Certificate of Analysis documents characteristics of a supplied research material. One does not substitute for the other.

Review Melanotan II acetate product specifications · Browse the COA library · Read the research-use policy

Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.